New lithium formula could mean fewer side effects for brain disorders

NCT ID NCT06921590

Completed Knowledge-focused Sponsor: Alzamend Neuro, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This early-stage study tests a new crystallized form of lithium (AL001) against standard lithium carbonate in 6 healthy adults. Participants take each drug for 14 days and undergo MRIs and blood draws to compare how much lithium reaches the brain. The goal is to see if AL001 is safer and delivers more lithium to the brain, which could lead to better treatments for brain conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AL001 (crystallized lithium) and lithium carbonate
What this could lead to: If AL001 delivers more lithium to the brain with fewer side effects, it could point toward a better-tolerated treatment for conditions like bipolar disorder or Alzheimer's.
What could go wrong: This is a very early, tiny study in just 6 healthy people. It only measures how the drug behaves, not whether it works for any disease. Results may not apply to patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROLOGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROLOGY PHARMACOKINETICS

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.